CD80


Also found in: Wikipedia.

CD80

a type I transmembrane protein on activated B cells, activated monocytes, activated follicular dendritic cells, and some activated T cells; provides a costimulatory signal to T cells during antigen presentation; expressed in B lymphoblastoid cells.
References in periodicals archive ?
CD83 is expressed at the surface of most DC and up-regulated together with co-stimulatory molecules, such as CD80, and CD86 during the maturation of DC (Fujimoto and Tedder, 2006).
RT-PCR primers for pluripotency (Oct3/4, Nanog, Sox2), MSC surface markers (CD4, CD8A, CD25, CD33, CD34, CD44, CD54, CD61, CD80, CD105, CD117, Flk-1 and HMGA2) and GAPDH internal control were shown in
Abatacept competitively binds to CD80 or CD86 on antigen presenting cells, which therefore cannot bind to CD28 on T cells, inhibiting successful T cell activation.
CTLA4-Ig binds with either CD80 (B7-1) or CD86 (B7-2) on antigen-presenting cells, thereby acting as a competitive inhibitor of the CD28-B7 costimulatory interaction and preventing the second activation signal received by T cells via CD28.
DCs on encountering antigens get activated leading to a change in their surface expression of various molecules like CD40, CD80, CD86, and MHC, involved in T cell activation.
2a] K, fluorescein isothiocyanate conjugated; BD Biosciences, San Jose, CA, USA); co-stimulatory molecules CD80 [16-10A1, Ar Ham Ig[G.
The alcohol-induced defects in dendritic cell function include reduced levels of CD80 and CD86 on the cells' surface (which are necessary to induce activation of T-cells) as well as reduced production of IL-12, which is critical for stimulating naive CD4+ T-cells to become IFN-[gamma]--producing
Activated antigen-specific B-cells are viewed as very potent antigen-presenting cells (APC) that can endocytose, process and present antigen at least 10 000-fold more efficiently than other professional APC, (5) largely because B-cells can selectively internalize antigen through the B-cell receptor, and efficiently stimulate T-cells through co-stimulatory molecules such as CD80 and CD86 (which are ligands for CD28 and CTLA-4 expressed on T-lymphocytes).
90) CTLA4-Ig binds to both CD80 and CD86 on the surface of antigen-presenting cells and blocks their binding to the T cell CD28, thereby inhibiting costimulation.
It blocks the activation of T cells by interrupting the interaction between the CD28 ligand on the T cell and the CD80 and CD86 ligand on the antigen presenting cell.
During this culture period, there was no significant difference in the expression levels of DC maturation markers, including CD86, CD80, and HLA-DR, as judged by flow cytometry (data not shown).
Both the numbers of patrolling Langerhans cells (LCs) and their function are compromised: decreased secretion of TNF by keratinocytes and reduced expression of CD80 is thought to affect the antigen presentation capacity of LCs (37,38).